Get a quick, expert overview of the ways in which biomarkers can be used to assess and guide the management of cardiovascular disease in the clinical setting. This concise, clinically-focused resource by Dr. Vijay Nambi consolidates today’s available information on this rapidly changing topic into one convenient resource, making it an ideal, easy-to-digest reference for cardiology practitioners, fellows, and residents. Covers lab standards and statistical interpretation of biomarkers with a clinical focus. Discusses relevant conditions such as hypertension and diabetes as key markers of injury and prognosis. Includes current information on biomarkers to assess and guide the management of heart failure, acute coronary syndrome, chest pain, shortness of breath, and more. Concludes the book with a timely chapter on how biomarkers may guide cardiologists in the future.

In the four pages committed to a discussion of myocardial infarction in the first edition of Harrison’s Principles of Internal Medicine, published in 1950, there was no mention of use of the laboratory for management of patients. Thirty years later, when the first edition of Braunwald’s Heart Disease, A Textbook of Cardiovascular Medicine was published, 2 out of the 1943 pages in the text contained a discussion of the laboratory examinations in acute myocardial infarction. Our knowledge base of the multitude of ways that physicians can and should use the clinical chemistry laboratory has expanded dramatically since these classic texts were published. The nomenclature has changed: terms such as “cardiac enzymes” have given way to “cardiac biomarkers. ” The number of assays has multiplied, and the operating characteristics of available assays are impr- ing at a gratifying but dizzying rate. We now use biomarkers to diagnose cardiovascular diseases and also to frame our treatment strategies. Thus, there is a clear need for a scholarly compilation of the state of the art of cardiac biomarkers. Dr. David Morrow has expertly edited an authoritative book that answers this need. The 34 chapters in Cardiovascular Biomarkers: Pathophysiology and Disease Mana- ment were written by a group of individuals who are internationally recognized thought leaders and experts in clinical and laboratory medicine.

The establishment of precise and reliable biomarker tests for the early stages of cardiovascular disease is of great importance and can be the cornerstone in the prevention of future cardiovascular disease (CVD). Furthermore, some biomarkers may provide important information concerning the pathogenesis of CVD or appear to be useful in risk stratification, in CVD diagnosis, or in monitoring therapy; many others may be risk factors themselves, representing therefore potential targets of therapy. The ideal biomarker should have the following characteristics: highly sensitive, specific, reliable, accessible, standardized, dependable, cost effective, and easily interpretable by clinicians. The present book focuses on the presentation and evaluation of the most promising classical and novel biochemical markers used in CVD (coronary artery disease, hypertension, heart failure, hyperlipidemia, peripheral arterial disease). The underlying pathophysiological characteristics of each biomarker, as well as potential clinical implications in daily practice are reviewed in this book.

Biomarkers in Heart Disease is the first title in the AHAClinical Series and is aimed at meeting the needs of clinicians,providing cardiologists, internists, emergency physicians,laboratorians, and other healthcare providers with a clearunderstanding of the role of biomarkers in contemporarycardiovascular medicine. The book covers both the strengths and pitfalls of currentlyavailable markers, and provides information on the most promisingbiomarkers that are likely to impact practice in the next fewyears. It is divided into four parts, organized around clinicalscenarios rather than individual biomarkers. This book will help the practicing physician decide whichbiomarkers to measure, when to measure them, how to interpret theresults and how to make decisions based on the test result.

This book covers ACS and Heart Failure, the chapters represent the most current, up to date and knowledgeable content on the topic available. It is written by the worlds most respected leaders in biomarkers, with a majority emphasis on what clinicians need to know. The Editors and their contributors have provided algorithms, annotated case discussions and caveats. They cover biomarkers to predict risk of heart disease, biomarkers of cardiorenal disease , and conclude with a section on new and emerging biomarkers. It be genuinely helpful and practical to those in the field, including not just people working in the field, but nurses, doctors, etc who practice medicine in the clinic, the emergency department and the hospital.​

Biomarkers can be defined as indicators of any biologic state, and they are central to the future of medicine. As the cost of developing drugs has risen in recent years, reducing the number of new drugs approved for use, biomarker development may be a way to cut costs, enhance safety, and provide a more focused and rational pathway to drug development. On October 24, 2008, the IOM's Forum on Drug Discovery, Development, and Translation held "Assessing and Accelerating Development of Biomarkers for Drug Safety," a one-day workshop, summarized in this volume, on the value of biomarkers in helping to determine drug safety during development.

Cardiac Biomarkers in Clinical Practice was just honored with 4 Stars from Doody's Book Review! Cardiac Biomarkers in Clinical Practice presents a case based approach to biomarkers in heart diseases including heart failure, ischemic heart disease, and outpatient. Divided into six sections, this book provides physicians and other health care providers with a clear understanding of the role of biomarkers in clinical cardiovascular medicine.